A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

March 11, 2020

Primary Completion Date

July 26, 2023

Study Completion Date

November 27, 2023

Conditions
Gastrointestinal NeoplasmsCholangiocarcinomaPancreatic Neoplasms
Interventions
DRUG

BI 905711

BI 905711

Trial Locations (18)

1200

Brussels - UNIV Saint-Luc, Brussels

3000

UZ Leuven, Leuven

10022

Memorial Sloan-Kettering Cancer Center, New York

25030

HOP Jean Minjoz, Besançon

28034

Hospital Ramón y Cajal, Madrid

35042

CTR Eugène Marquis, Rennes

46010

Hospital Clínico de Valencia, Valencia

68167

Universitätsklinikum Mannheim GmbH, Mannheim

69373

CTR Leon Berard, Lyon

77030

The University of Texas MD Anderson Cancer Center, Houston

78229

START South Texas Accelerated Research Therapeutics, LLC, San Antonio

86021

HOP la Milétrie, Poitiers

100142

Beijing Cancer Hospital, Beijing

510655

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou

06511

Yale Cancer Center, New Haven

277-8577

National Cancer Center Hospital East, Chiba, Kashiwa

02841

Korea University Anam Hospital, Seoul

08035

Hospital Vall d'Hebron, Barcelona

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04137289 - A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer | Biotech Hunter | Biotech Hunter